Viewing Study NCT02319005


Ignite Creation Date: 2025-12-25 @ 3:09 AM
Ignite Modification Date: 2025-12-26 @ 1:48 AM
Study NCT ID: NCT02319005
Status: COMPLETED
Last Update Posted: 2018-07-18
First Post: 2014-12-12
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor: Alnylam Pharmaceuticals
Organization: